Last $10.60 USD
Change Today +0.81 / 8.27%
Volume 792.4K
INFI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Open
$9.92
Previous Close
$9.79
Day High
$10.68
Day Low
$9.68
52 Week High
04/29/13 - $44.50
52 Week Low
04/15/14 - $8.91
Market Cap
511.8M
Average Volume 10 Days
745.7K
EPS TTM
$-2.64
Shares Outstanding
48.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (INFI)

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

180 Employees
Last Reported Date: 02/25/14

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $536.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $216.1K
President of Research and Development
Total Annual Compensation: $452.2K
Chief Scientific Officer
Total Annual Compensation: $352.3K
Compensation as of Fiscal Year 2012.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Announces Board Changes

Infinity Pharmaceuticals, Inc. announced that it has appointed José Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center. Mr. Berkowitz, as the President of Walgreens Boots Alliance Development, GmbH (WAG) in Europe, has a wealth of experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement. Infinity also announced that Thomas Lynch, M.D. and Martin Babler have retired from the board. Dr. Baselga has served as Physician-in-Chief at Memorial Sloan-Kettering Cancer Center since January 2013. Mr. Jeffrey Berkowitz is President of Walgreens Boots Alliance Development GmbH and is Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co.

Infinity Pharmaceuticals, Inc. Presents at Bernstein's 2014 Emerging Biotech Conference, Mar-10-2014 04:00 PM

Infinity Pharmaceuticals, Inc. Presents at Bernstein's 2014 Emerging Biotech Conference, Mar-10-2014 04:00 PM. Venue: Snowbird, Utah, United States.

Infinity Pharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Fourth Quarter and Twelve Months Ended December 31, 2013; Provides Production Updates

Infinity Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the fourth quarter and twelve months ended December 31, 2013. For the quarter, the company reported loss from operations was $33,084,000 compared with $47,126,000 for the same period last year. Net loss was $32,925,000 or $0.68 basic and diluted per share compared with $46,984,000 or $1.15 basic and diluted per share for the same period last year. For the twelve months, the company reported loss from operations was $127,676,000 compared with $52,808,000 for the same period last year. Net loss was $126,780,000 or $2.64 basic and diluted per share compared with $53,964,000 or $1.70 basic and diluted per share for the same period last year. The company announced its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Recent Infinity pipeline highlights include: Reported encouraging Phase 1 clinical data, which build on the clinical activity and tolerability profile of IPI-145, at the 55th Annual Meeting of the American Society for Hematology (ASH): Infinity reported Phase 1 data of IPI-145 monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL), demonstrating that IPI-145 was generally well tolerated and clinically active, with an overall response rate (ORR) of 73%, including three complete responses, among 15 patients receiving IPI-145 dosed at <= 25 mg twice daily (BID). Data also showed that 53% of patients remained progression free for over one year. These data support the clinical rationale for DYNAMOTM, the ongoing Phase 2 study of IPI-145 in patients with refractory iNHL. Additionally, the Phase 1 study of IPI-145 for the treatment of chronic lymphocytic leukemia (CLL) showed that IPI-145 was generally well tolerated and highly active in patients with relapsed/refractory CLL, including a nodal response rate of 89% and an ORR of 48% as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria1, with one complete response and 12 partial responses among 27 patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $10.60 USD +0.81

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INFI.
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.